Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on postprandial endothelial function

Journal of the American College of Cardiology

Volumn 34, Issue 1, 1999, Pages 140-145

  Wilmink, Hanneke W ^a   Banga, Jan D ^a   Hijmering, Michel ^a   Erkelens, Willem D ^a   Stroes, Erik S G ^a   Rabelink, Ton J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOSARTAN; LOSARTAN POTASSIUM; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; QUINAPRIL; TRIACYLGLYCEROL;

ADULT; ARTERY DIAMETER; ARTICLE; BRACHIAL ARTERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOTHELIUM LESION; FAT INTAKE; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPEREMIA; MALE; NORMAL HUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBLINGUAL DRUG ADMINISTRATION; VASCULAR ENDOTHELIUM; VASODILATATION;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; ISOQUINOLINES; LOSARTAN; MALE; POSTPRANDIAL PERIOD; TETRAHYDROISOQUINOLINES; VASODILATION;

EID: 0033165554     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00154-0     Document Type: Article

References (29)

1. Iiyama K., Nagano M., Yo Y., et al. Impaired endothelial function with essential hypertension assessed by ultrasonography. Am Heart J. 132:1996;779-782.
2. Reddy K.G., Nair R.N., Sheehan H.M., Hodgson J.M. Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J Am Coll Cardiol. 23:1994;833-843.
3. Celermajer D.S., Sorensen K.E., Georgakopoulos D., et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation. 88:1993;2149-2155.
4. Anggard E. Nitric oxide mediator, murderer, and medicine . Lancet. 343:1994;1199-1206.
5. Mamo J.C.L., Elsegood C.L., Gennat H.C., Yu K. Degradation of chylomicron remnants by macrophages occurs via phagocytosis. Biochemistry. 35:1996;10210-10214.
6. Proctor S.D., Mamo J.C. Retention of fluorescent-labelled chylomicron remnants within the intima of the arterial wall - evidence that plaque cholesterol may be derived from postprandial lipoproteins. Eur J Clin Invest. 28:1998;497-503.
7. Slyper A.H. A fresh look at the atherogenic remnant hypothesis. Lancet. 340:1992;289-291.
8. Hodis H.N., Mack W.J. Triglyceride-rich lipoproteins and progression of atherosclerosis. Eur Heart J. 19:1998;A40-A44.
9. Karpe F., Steiner G., Uffelman K., Olivecrona T., Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis. 106:1994;83-97.
10. Hodis H.N., Mack W., Dunn M., Liu C., Selzer R.H., Krauss R.M. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation. 95:1997;2022-2026.
11. Kugiyama K., Hideki D., Motoyama T., et al. Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation. 97:1998;2519-2526.
12. Plotnick G.D., Corretti M., Vogel R.A. Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal. JAMA. 278:1997;1682-1686.
13. Karpe F., Hamsten A. Postprandial lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol. 6:1995;123-129.
14. Rajagopalan S., Kurz S., Munzel T., et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest. 97:1996;1916-1923.
15. Moncada S., Palmer R.M.J., Higgs E.A. Nitric oxide physiology, pathophysiology, and pharmacology . Pharmacol Rev. 43:1991;109-142.
16. Mombouli J.V., Bissiriou I., Agbolon V., Vanhoutte P.M. Endothelium-derived hypopolarizing factor a key mediator of the vasodilator action of bradykinin . Immunopharmacology. 33:1996;46-50.
17. O'Driscoll G., Green D., Rankin J., Stanton K., Taylor R. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest. 100:1997;678-684.
18. Mancini G.B., Henry G., Macaya C., et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) study. Circulation. 94:1996;258-265.
19. Tamai O., Matsuoka H., Itabe H., Wada Y., Kohno K., Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation. 95:1997;76-82.
20. Stroes E., de Bruin T., de Valk H., et al. NO activity in familial combined hyperlipidemia potential role of cholesterol remnants . Cardiovasc Res. 36:1997;445-452.
21. Grieve D.J., Avella M.A., Elliott J., Botham K.M. The influence of chylomicron remnants on endothelial function in the isolated perfused rat aorta. Atherosclerosis. 139:1998;273-281.
22. Anderson R.A., Evans L.M., Elli G.R., et al. Postprandial lipaemia is associated with increased free radicals and deterioration in endothelial function in non-insulin dependent diabetes (abstr). Eur Heart J. 88:1998;A3305.
23. Hornig B., Kohler C., Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation. 95:1997;1115-1118.
24. Berkenboom G., Langer I., Carpentier Y., Grosfils K., Fontaine J. Ramipril prevents endothelial dysfunction induced by oxidized low-density lipoproteins a bradykinin-dependent mechanism . Hypertension. 30:1997;371-376.
25. Hernandez A., Barberi L., Ballerio R., et al. Delapril slows the progression of atherosclerosis and maintains endothelial function in cholesterol-fed rabbits. Atherosclerosis. 137:1998;71-76.
26. Pitt B., Pepine C., O'Neill B.J., Haber H., Pressler M., Mancini G.B. Modulation of ACE inhibitor efficacy on coronary endothelial dysfunction by low density lipoprotein cholesterol (abstr). J Am Coll Cardiol. 29:(Suppl A):1997;70A.
27. Cashin-Hemphill L., Dinsmore R.E., Chan R.C. LDL cholesterol and angiographic progression in the QUIET trial (abstr). J Am Coll Cardiol. 29:(Suppl A):1997;85A.
28. Gilligan D.M., Guetta V., Panza J.A., Garcia C.E., Quyyumi A.A., Cannon R.O. Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation. 90:1994;35-41.
29. Timmerman P.B., Wong P.C., Chiu A.T., et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 45:1993;205-251.